Viracor has extensive experience performing pathogen load monitoring, antiviral resistance assessment, nucleic acid sequencing and other pathogen characterizations for clinical trials.
With a wide range of viral and bacterial targets, you have access to a comprehensive menu of real-time PCR and sequencing assays for pathogen detection and monitoring. Viracor’s multiple-target, dual gene assays, an approach we adopted early in the transition to molecular diagnostics, are designed to eliminate false negative results or under-quantification.
As experts in infectious disease assays, we offer a broad array of testing solutions for biomarker detection, immunogenicity, and other safety and efficacy assessments to support anti-viral and vaccine candidate clinical programs.
We also offer validated molecular and serology tests for SARS-CoV-2, along and other bioassay solutions that are helping our clients COVID-19 vaccine and anti-viral therapy development efforts.
In fact, our SARS-CoV-2 RT-PCR assay was reported by the US FDA to be the most sensitive assay (180 NDU/mL) of the 117 evaluated.*
We also offer SARS-Cov-2 spike gene and whole genome sequencing (WGS) assays on multiple sample types, to fit your COVD-19 vaccine and anti-viral development needs.
Coronavirus (COVID-19) Testing Portfolio:
*The Eurofins-Viracor SARS-CoV-2 RT-PCR diagnostic test, was ranked as the most sensitive out of more than 117 kits evaluated by the US FDA SARS-CoV-2 Reference Panel (https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data#table2c). Furthermore, this RT-PCR test maintains very high sensitivity in the detection of variants such as B.1.1.7 and B.1.351.
Learn more about our coronavirus testing portfolio in our COVID-19 Testing for Clinical Trials brochure.
Eurofins Viracor COVID-19 RT-PCR Test Coverage for New Variants/Strains of SARS-CoV-2
Variants of the SARS Cov-2 virus are becoming more prevalent in parts of the United States, and a potential consequence of emerging variants is the ability to evade detection by viral diagnostic tests. Eurofins Viracor, as a leading supplier of COVID-19 testing solutions, chose an assay design that anticipates genetic variation, and we maintain vigilant surveillance efforts for new variants.
Eurofins Viracor SARS CoV-2 RT-qPCR Assay Design
Our assay employs a very similar approach as taken by the US CDC. Two independent assays target different regions of the nucleocapsid gene (N gene). This dual target design was chosen to mitigate the risk of loss of sensitivity (under-quantitation and false-negativity reporting); and helps provide confidence that our tests can identify COVID-19 positive patients even when mutations in the genome arise. The odds of both assays sustaining significant reduction in performance due to a variant’s mutation profile are very low.
To ensure that our assay continues to provide reliable results, Viracor continues to monitor the variant situation closely, utilizing a custom bioinformatics algorithm. We query the GISAID1 database (the primary repository for SARS CoV-2 sequencing results) for all new entries of N gene sequences. The oligos comprising the assay are tested in silico for alignment with the new GISAID sequences. If a variant is predicted to possibly fail in detection, we initiate procedures to fully evaluate empirically and, if needed, revise the assay. As of April 1, 2021, the SARS-CoV-2 RT-qPCR assay is predicted to detect all known variants.
Viracor offers clients a wealth of infectious disease testing options for clinical studies, including:
Additional Chronic Viral Infection Testing: